WO2025253355 - TOPICAL FORMULATION COMPRISING SI-RNA
National phase entry is expected:
Publication Number
WO/2025/253355
Publication Date
11.12.2025
International Application No.
PCT/IB2025/055858
International Filing Date
06.06.2025
Title **
[English]
TOPICAL FORMULATION COMPRISING SI-RNA
[French]
FORMULATION TOPIQUE COMPRENANT DE L'ARN SI
Applicants **
ALDENA THERAPEUTICS
Inventors
BLANCHARD, Carine
BOUIX-PETER, Claire
DEAN, Yann
PRAUSNITZ, Mark
BERNSTEIN, James
LEMING, Robert
HARRIS, John
DE SMEDT, Thibaut
Priority Data
63/657,253
07.06.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4117 | |
| EPO | Filing, Examination, Granting | 53332 | |
| Japan | Filing, Examination, Granting | 3853 | |
| South Korea | Filing, Examination, Granting | 5529 | |
| USA | Filing, Examination, Granting | 14740 |
Total:
81,571
Contact Us
Abstract[English]
Aspects of the present disclosure provide a pharmaceutical composition comprising optionally a monovalent or bivalent, monospecific or bispecific siRNA, a plurality of micrometer or millimeter scale particles, and a pharmaceutical acceptable carrier.[French]
Des aspects de la présente divulgation concernent une composition pharmaceutique comprenant éventuellement un ARNsi monovalent ou bivalent, monospécifique ou bispécifique, une pluralité de particules micrométriques ou millimétriques, et un support pharmaceutique acceptable.